Astrazeneca Shares Rally 2.99% on Surpassing Q2 Earnings and U.S. Sales Growth Trading Volume Spikes 93.56% to Rank 92nd

Astrazeneca (AZN) shares closed 2.99% higher on July 29, with a trading volume of $1.07 billion, marking a 93.56% surge from the previous day and ranking 92nd in market activity. The stock’s performance followed a second-quarter earnings report that exceeded expectations, driven by robust U.S. sales and oncology product demand. Core earnings per share reached $2.17 on $14.46 billion in revenue, outpacing analyst forecasts of $1.63 and $14.25 billion, respectively.

The U.S. market, contributing 44% of total revenue, saw a 13% year-over-year growth, while oncology revenue surged 18%. CEO Pascal Soriot highlighted a $50 billion investment plan to expand U.S. manufacturing and research by 2030, aligning with the company’s $80 billion revenue target. Despite challenges from pricing pressures and global trade risks, Astrazeneca reaffirmed its full-year outlook, projecting high single-digit revenue growth and low double-digit core EPS increases at constant exchange rates.

A backtest of a strategy buying the top 500 stocks by daily trading volume and holding them for one day showed a 166.71% return from 2022 to the present. This outperformed a benchmark return of 29.18%, with an excess return of 137.53% and a compound annual growth rate of 31.89%. The strategy recorded a maximum drawdown of 0.00% and a Sharpe ratio of 1.14, indicating strong risk-adjusted performance.